{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:14:59Z","timestamp":1783401299696,"version":"3.54.6"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CR-GN (Carbapenem-resistant Gram-negative) infections pose a significant global public health threat due to their high mortality rates. Furthermore, many treatments carry substantial renal toxicity. This study aims to compare renal injury associated with the most commonly used therapeutic regimens in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was designed selecting patients with invasive CR-GN infections, successfully treated (evideced by microbiological clearance or clinical resolution) in Intensive Care Unit (ICU) and Medicine Department at \u201cCristo Re\u201d General Hospital in Rome. Renal injury was defined as either a doubling of serum creatinine or a 50% reduction in glomerular filtration rate (GFR) at the end of treatment. Patients on dialysis, those treated for less than 5 days, and those with a baseline GFR of less than 30\u00a0mL\/min were excluded. Chi-square tests were employed to compare frequencies, and multivariable logistic regression was performed to identify predictors of kidney injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We collected data from 59 patients (28 with\n                      <jats:italic>Acinetobacter<\/jats:italic>\n                      baumannii, 7 KPC-producing\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      , 24\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      ) with a median age of 74 years (IQR 64.8\u201380), 33 of whom (55.9%) were treated with IV fosfomycin (in combination 28 patients with colistin, 2\u00a0pts with colistin and tigecycline and 3 with Ceftazidime\/avibactam (CAZ\/AVI), 26 patients with other regimens (21 of which including colistin). The median treatment duration was 10 days (IQR 7\u201314). At the end of treatment, 11 patients (18.6%) developed acute kidney injury, with a statistically significant difference favoring fosfomycin containing regimens (9.1% vs. 30.8% P = 0.037). Among colistin-containing regimens, the renal injury rate was significantly lower when fosfomycin was included (10.7% vs. 33.3%, P = 0.05). Logistic regression analysis identified the use of fosfomycin as an independent predictor of kidney injury prevention (OR = 0.074; IC 0.008\u20130.678 p = 0.021).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirms that regimens used for treating carbapenem-resistant Gram-negative bacterial infections cause a high rate of acute kidney injury, largely due to the frequent use of known nephrotoxic drugs, like colistin. However, our data suggest that combining these drugs with intravenous fosfomycin may offer renal protective benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1811298","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:23:23Z","timestamp":1783398203000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravenous fosfomycin-containing regimens are associated with reduced acute kidney injury in carbapenem-resistant Gram-negative infections: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Alessandro","family":"D\u2019Avino","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, IDI IRCCS Istituto Dermopatico dell\u2019Immacolata","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Paciacconi","sequence":"additional","affiliation":[{"name":"Intensive Care Unit Department, Aurelia Hospital","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Mazzocchetti","sequence":"additional","affiliation":[{"name":"Intensive Care Unit Department, Aurelia Hospital","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dionisi","sequence":"additional","affiliation":[{"name":"Intensive Care Unit Department, Aurelia Hospital","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Grande","sequence":"additional","affiliation":[{"name":"Health Direction and Risk Management, Cristo Re General Hospital, GIOMI S.p.a.","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Nasi","sequence":"additional","affiliation":[{"name":"Health Direction and Risk Management, Cristo Re General Hospital, GIOMI S.p.a.","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Claire","family":"Theriault","sequence":"additional","affiliation":[{"name":"Intensive Care Unit Department, Cristo Re General Hospital, GIOMI S.p.a.","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcangelo","family":"Schiattarella","sequence":"additional","affiliation":[{"name":"Microbiology and Clinical Pathology Department, Cristo Re General Hospital, GIOMI S.p.a.","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ccm.2018.08.007","article-title":"New antibiotics for pneumonia","volume":"39","author":"Bassetti","year":"2018","journal-title":"Clin. Chest Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute dialysis quality initiative workgroup acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit. Care"},{"key":"B3","volume-title":"Annual Epidemiological Report on Communicable Diseases in Europe","year":"2014"},{"key":"B4","volume-title":"Antimicrobial Resistance in the EU\/EEA (EARS-Net) - Annual Epidemiological Report 2022","year":"2023"},{"key":"B5","unstructured":"2020"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e02549","DOI":"10.1128\/AAC.02549-18","article-title":"Evaluation of the bactericidal activity of fosfomycin in combination with selected antimicrobial comparison agents tested against gram-negative bacterial strains by using time-kill curves","volume":"63","author":"Flamm","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMcp1104429","article-title":"Uncomplicated urinary tract infection","volume":"366","author":"Hooton","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e01110","DOI":"10.1128\/AAC.01110-18","article-title":"New treatment options against carbapenem-resistant Acinetobacter baumannii infections","volume":"63","author":"Isler","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","article-title":"Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically Ill patients: a systemic review and bayesian network meta-analysis","volume":"21","author":"Jung","year":"2017","journal-title":"Crit. Care"},{"key":"B10","doi-asserted-by":"publisher","first-page":"100020","DOI":"10.1016\/j.infpip.2019.100020","article-title":"Impact of bloodstream infections caused by carbapenem-resistant Gram-negative pathogens on ICU costs, mortality and length of stay","volume":"1","author":"Kousouli","year":"2019","journal-title":"Infect. Prev. Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"17127","DOI":"10.1038\/s41598-019-53714-0","article-title":"In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia","volume":"9","author":"Ku","year":"2019","journal-title":"Sci. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0196-6553(99)70088-X","article-title":"Guideline for prevention of surgical site infection, 1999","volume":"27","author":"Mangram","year":"1999","journal-title":"Am. J. Infect. Control"},{"key":"B13","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute kidney injury network acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit. Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e00779","DOI":"10.1128\/AAC.00779-19","article-title":"Evaluation of the synergy of ceftazidime\u2013avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa","volume":"63","author":"Mikhail","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1211\/0022357991772187","article-title":"Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats","volume":"51","author":"Nakamura","year":"1999","journal-title":"J. Pharm. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/ph14030185","article-title":"Evaluation of the synergistic antibacterial effects of fosfomycin in combination with selected antibiotics against carbapenem-resistant Acinetobacter baumannii","volume":"14","author":"Nwabor","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009X.2024.2349439","article-title":"A comparative study of ceftazidime\/avibactam-based and fosfomycin plus meropenem-based regimens for managing infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients","volume":"37","author":"\u00d6nal","year":"2024","journal-title":"J. Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0244673","DOI":"10.1371\/journal.pone.0244673","article-title":"Synergistic antibacterial effects of colistin in combination with aminoglycoside, carbapenems, cephalosporins, fluoroquinolones, tetracyclines, fosfomycin, and piperacillin on multidrug resistant Klebsiella pneumoniae isolates","volume":"16","author":"Ontong","year":"2021","journal-title":"PLoS One"},{"key":"B19","first-page":"136","article-title":"In vitro activity of ceftazidime\/avibactam alone and in combination with fosfomycin and carbapenems against KPC-producing Klebsiella pneumoniae","volume":"43","author":"Romanelli","year":"2020","journal-title":"New Microbiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40121-020-00357-8","article-title":"Efficacy of a Fosfomycin-Containing regimen for treatment of severe pneumonia caused by multidrug-resistant acinetobacter baumannii: a prospective, observational study","volume":"10","author":"Russo","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"B22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.diagmicrobio.2018.01.008","article-title":"In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates","volume":"91","author":"Singkham-In","year":"2018","journal-title":"Diagn Microbiol. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"17567","DOI":"10.1038\/s41598-024-67347-5","article-title":"Synergistic antibacterial activity of ceftazidime-avibactam in combination with colistin, gentamicin, amikacin, and fosfomycin against carbapenem-resistant Klebsiella pneumoniae","volume":"14","author":"T\u00fczemen","year":"2024","journal-title":"Sci. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2323e9","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5720417","DOI":"10.1155\/2018\/5720417","article-title":"Synergistic activity of colistin\/fosfomycin combination against carbapenemase-producing Klebsiella pneumoniae in an In Vitro pharmacokinetic\/pharmacodynamic model","volume":"2018","author":"Wang","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"B26","unstructured":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics\n          \n          \n          2017"},{"key":"B27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cbi.2004.05.005","article-title":"Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue","volume":"148","author":"Yanagida","year":"2004","journal-title":"Chem. Biol. Interact."},{"key":"B28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s101560170020","article-title":"The effect of fosfomycin on glycopeptide antibiotic-induced nephrotoxicity in rats","volume":"7","author":"Yoshiyama","year":"2001","journal-title":"J. Infect. Chemother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1811298\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:23:30Z","timestamp":1783398210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1811298\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":28,"alternative-id":["10.3389\/fphar.2026.1811298"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1811298","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1811298"}}